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It has been suggested that anti-hypertensive medications may worsen leg ischemia in
peripheral artery disease (PAD) patients. We undertook a meta-analysis to assess the effect
of anti-hypertensive medications on measures of leg ischemia including maximum walking
distance (MWD), pain free walking distance (PFWD) and ankle brachial pressure index
(ABPI). A meta-regression was performed to evaluate whether the effect of the anti-hyper-
tensive medications on mean arterial pressure (MAP) was associated with changes in
ABPI, MWD or PFWD.
Method
A systematic literature search was performed to identify placebo controlled randomized con-
trol trials (RCT) testing anti-hypertensive medications, which reported baseline and follow-
up measurements of: MAP and MWD, PFWD or ABPI in patients with intermittent claudica-
tion (IC) due to PAD.
Result
A meta-analysis was performed on 5 RCTs comprising a total of 180 and 127 patients
receiving anti-hypertensive medications and placebo respectively. This analysis suggested
that anti-hypertensive medication did not significantly affect MWD, PFWD or ABPI. In con-
trast, the meta-regression analysis showed that the reduction in MAP due to the anti-hyper-
tensive drugs was positively correlated with increased MWD during follow-up (β = 8.371, p =
0.035). Heterogeneity across studies, as assessed by I2, was high. The follow-up period
within the included trials was generally short with 3 out of 5 studies having a follow-up period
of 6 weeks.
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Conclusion
This study suggests that anti-hypertensive treatment does not worsen but may improve leg
ischemia in PAD patients. Larger multicenter trials with longer anti-hypertensive treatment
periods are required to clarify the effect of anti-hypertensives on leg ischemia in PAD
patients.
Introduction
Lower limb peripheral artery disease (PAD) results from narrowing and occlusion of the arter-
ies supplying blood to the legs, usually due to atherosclerosis and associated thrombosis[1, 2].
Approximately 200 million people worldwide were estimated to have PAD in 2010, a rise of
25% since 2000[3]. The most recognised presenting complaint for PAD patients is intermittent
claudication (IC). Patients with IC have significantly impaired walking ability, high rates of
cardiovascular events, such as myocardial infarction and stroke, and reduced disease-related
quality of life[4]. Approximately 20% of patients with PAD will die from a cardiovascular
event within 5 years[5] and therefore aggressive management of cardiovascular risk factors is
the primary focus of treatment[6].
Hypertension was identified by the global burden of disease study as the leading risk factor
for mortality and disability-adjusted life years lost in 2010[7]. Hypertension is considered an
important risk factor for PAD and its complications and approximately 50% of patients pre-
senting with PAD are reported to have hypertension[8–12]. Clinical trials including PAD
patients (in addition to those with other atherosclerosis-related diseases) have reported a rela-
tive reduction in cardiovascular events in those receiving blood pressure lowering medications
of 20–30%[13, 14]. Therefore current recommendations advise that PAD patients should
receive anti-hypertensive medications if their blood pressure (BP) is >140/90[15–17]. How-
ever, the use of some anti-hypertensives, particularly β blockers, has been traditionally contra-
indicated in PAD patients due to concerns regarding reducing peripheral perfusion[18, 19].
This opinion has been challenged by others who have reported that BP lowering medications
do not worsen leg ischemia[20–22]. Some previously published randomised trials in PAD
patients have reported improvements in maximum walking distance (MWD), pain free walk-
ing distance (PFWD), ankle brachial pressure index (ABPI) and calf blood flow (CBF) after
commencing anti-hypertensive medications[23–30]. Other trials have reported no effect of
anti-hypertensive medications on PAD patients[31, 32]. A previous Cochrane review con-
cluded that there was lack of evidence on the efficacy of anti-hypertensive medication in
patients with PAD, but did not perform a meta-analysis or meta-regression to definitely assess
this[33]. In view of the current controversy regarding the effect of BP lowering medication on
symptoms of PAD, we undertook a systematic review and meta-analysis to assess if anti-hyper-
tensive medications worsen leg ischemia in PAD patients.
Materials and methods
This meta-analysis was performed in accordance with the Preferred Reporting Items for Sys-
tematic reviews and Meta-Analyses (PRISMA) guidelines[34]. A protocol was developed fol-
lowing the guidelines of the PRISMA-P statement[34] and was published in the PROSPERO
database (CRD42016038338).
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Search strategy
A systematic search was performed to identify placebo controlled randomised trials (RCTs)
evaluating the effects of anti-hypertensive medications on three recognised measures of the
severity of leg ischemia including ABPI, MWD and PFWD in patients with IC. The search
strategy undertaken and the study selection criteria are detailed in S1 File.
Data extraction
Two authors (DT and BD) extracted data independently using a predefined data extraction
table (see S1 File and S1 Table for further details).
Study quality assessment
A quality assessment tool was formulated using components from the following validated
tools: a) The 25 items CONSORT 2010 checklist of information to be included when reporting
a randomised trial; and b) The Cochrane collaboration tool for assessing risk of bias[35, 36].
The quality assessment details are given in S1 File.
Quantitative data synthesis
The first author (DT) performed statistical analysis of data using the Meta-Analyst software
(version beta 3.13)[37]. A description of the data synthesis is provided in S1 File.
Assessment of publication bias
The publication bias was assessed using funnel plots and Eggers’s test using the CMA software
package (Comprehensive Meta-Analysis version 3.3.070). The first author (DT) carried out the
publication bias assessment.
Results
Characteristics of the included studies
Our search identified 11,434 articles. Detailed characteristics of the included studies are given
in S2 File. A PRISMA flow chart outlining the literature search and study selection process is
given in Fig 1.
Quality assessment
The quality assessment showed that four studies were of high quality and the remaining one of
moderate quality. Agreement on the quality assessment between the observers ranged from 95
to 100% (S2 File). Other details of the quality of the studies are shown in S2 File.
Description of the included studies
The characteristics of the included studies and participants are given in S2 File.
Relationship between changes in MAP and ABPI and walking ability
A meta-regression analysis was carried out to analyse whether the effect of the anti-hyperten-
sives on MAP was associated with the changes in walking distance and ABPI recorded over the
course of the trials. The change in MAP and walking distance after treatment with each anti-
hypertensive drug was obtained by considering the reported parameters following a ‘washout
period’ as baseline for the whole cohort. In total, 8 and 7 groups were used to evaluate the
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association between reduction in MAP after drug treatment with MWD and PFWD respec-
tively. The magnitude of reduction in MAP from baseline due to the anti-hypertensive drugs
showed a significant positive correlation with improved MWD (β = 8.371, p = 0.035) (Fig 2)
but not PFWD or ABPI (PFWD, β = 4.276, p = 0.195; ABPI, β = -0.004, p = 0.357).
The effect of anti-hypertensives on ABPI, MWD and PFWD
Meta-analyses were conducted to see if reported reductions in BP following antihypertensive
therapy led to clinically relevant improvements in ABPI, MWD or PFWD. Studies by Robert
et al. and Bagger et al. were given a baseline—post-intervention correlation value of 0.5 for this
analysis. Robert et al. assessed 4 anti-hypertensive drugs and placebo in a crossover design.
Hence for this meta-analysis, each treatment period was considered as a separate trial. Accord-
ingly, a total of 8 and 7 groups were used to assess the effect of anti-hypertensives on MWD
and PFWD respectively (S1 Table). The meta-analysis suggested that anti-hypertensives had
no significant effect on ABPI [SMD = -0.151 (95% CI, -0.425–0.123)], MWD [SMD = -0.155
(95% CI, -0.617–0.306)] or PFWD [d = − 0.013 (95% CI, -0.342–0.316)] (Figs 3–5). The find-
ings for MWD were similar in sub-group analyses that assessed treatment periods of> 1
or< 1 month (Fig 4B).
Fig 1. PRISMA flow chart outlining the literature search and the study selection process.
https://doi.org/10.1371/journal.pone.0178713.g001
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A sub-analysis was performed to determine whether ACE inhibitors had an effect on leg
ischemia[18, 24, 38]. These studies had intervention period of 4, 6 and 24 weeks. No significant
effect was found on either MWD (SMD = − 0.164, 95% CI -0.642–0.314) or PFWD (SMD =
-0.214, 95% CI -0.663–0.236) (Figs 4C and 5B). Due to a lack of available studies, sub-analyses
could not be performed for other drug classes.
Assessment of publication bias
Eggers’s test and the funnel plots (S3 File) suggested no publication bias. The intercepts of the
funnel plots assessing publication bias in trials included to analyse the effect of anti-
Fig 2. Results of the meta-regression analysis showing the association between reduction in blood pressure and improvement in MWD
after being randomised to an anti-hypertensive drug. Fig 2 shows the association between reducing MAP and improving MWD in all the included
trials. Abbreviations: β–regression coefficient, MAP—mean arterial pressure and MWD—maximum walking distance.
https://doi.org/10.1371/journal.pone.0178713.g002
Fig 3. Forest plot illustrating the effect of anti-hypertensive medications on ABPI. The x-axis is the effect size expressed as SMD (standardised
mean difference). The forest plot also details the 95% confidence interval. The dotted line represents the overall effect calculated in this meta-analysis.
The heterogeneity estimated as I2 and Q is also provided. Abbreviation: ABPI—ankle brachial pressure index.
https://doi.org/10.1371/journal.pone.0178713.g003
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Fig 4. Forest plots illustrating the effect of anti-hypertensive medications on MWD. The x-axis is the effect
size expressed as SMD (standardised mean difference). The forest plot also details the 95% confidence interval.
The dotted line represents the overall effect calculated in this meta-analysis. The heterogeneity estimated as I2
and Q associated with each analysis is also provided. (A) The effect of anti-hypertensive medications on MWD,
(B) Subgroup analysis including trials with follow up period greater than and less than 1 month, (C) Subgroup
analysis including trials which used ACE inhibitors. Abbreviations: ACE—angiotensin converting enzyme and
MWD—maximum walking distance.
https://doi.org/10.1371/journal.pone.0178713.g004
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hypertensive medications on ABPI, MWD and PFWD were -0.825 (-8.779–7.129, p = 0.699),
0.388 (-11.038–11.814, p = 0.936) and -1.205 (-14.505–12.095, p = 0.825) respectively.
Discussion
The use and choice of anti-hypertensive medications in PAD patients has been debated for a
long time and one of the main concerns have been that anti-hypertensive drugs may worsen
leg ischemia. The main finding of this meta-analysis was that anti-hypertensive therapy did
not affect leg ischemia as assessed by ABPI, MWD and PFWD. A benefit of anti-hypertensive
medications on leg ischemia was suggested by the meta-regression since there was a significant
positive correlation between degree of reduction in BP and improvement in MWD.
The RCTs included in this meta-analysis had many limitations. Notably, there was no wash-
out period between treatment periods in the crossover trial by Robert et al.[18]. Hence signifi-
cant carryover effects may have been present which may have masked the true effect of anti-
hypertensive drugs tested. Furthermore, a follow-up period of at least 6 months is recom-
mended in studies of IC to ensure that adequate time is available to demonstrate effects on the
Fig 5. Forest plots illustrating the effect of anti-hypertensive medications on PFWD. The x-axis is the
effect size expressed as SMD (standardised mean difference). The forest plot also details the 95%
confidence interval. The dotted line represents the overall effect calculated in this meta-analysis. The
heterogeneity estimated as I2 and Q associated with each analysis is also provided. (A) The effect of anti-
hypertensive medications on PFWD, (B) Subgroup analysis including trials which included ACE inhibitors.
Abbreviations: ACE—angiotensin converting enzyme and PFWD—pain free walking distance.
https://doi.org/10.1371/journal.pone.0178713.g005
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leg[39]. The trials by Bagger et al., Robert et al. and Overlack et al. had a follow-up period of
two, four and six weeks respectively, which were lower than advocated[18, 23, 38]. Three trials
included in this meta-analysis reported improvement in walking distance after anti-hyperten-
sive drug treatment[23–25]. The treatment period for these trials were 52, 24 and 2 weeks, sug-
gesting that longer duration of treatment with anti-hypertensives may be required to
demonstrate their efficacy[39]. Only 2 trials achieved a SBP target according to current guide-
lines of 140 mmHg [24, 25]. Attaining BP goals may have improved the outcomes. The
blinding details of the trial authored by Zankl et al. were unclear[25, 40]. The research was a
single blinded study, however the paper did not specify whether the investigators or the
patients were blinded. The risk of bias is significant when adequate blinding is not used[40].
RCTs without appropriate blinding have been demonstrated to show a larger treatment effect
[41].
The overall lack of effect of anti-hypertensive medications on measures of leg ischemia
reported in this meta-analysis can be attributed to many reasons. Firstly, there were few pub-
lished trials that met the entry criteria and the majority of these trials included small number
of patients. Secondly, there are potential methodological issues in combining crossover trials
and parallel studies in a meta-analysis. The correlation co-efficient between baseline and fol-
low-up scores in the included crossover trials were also not available hence a conservative esti-
mate value of 0.5 was used[42]. Furthermore, the follow-up period was different in all the trials
ranging from 2 to 52 weeks. Different trials also used different anti-hypertensive medications.
The current meta-analysis was performed by pooling all trials together regardless of their anti-
hypertensive class. In addition, the inclusion and exclusion criteria in the included RCTs were
different as a result of which the baseline characteristics of the participants were noticeably dif-
ferent. The crossover trials excluded patients with concomitant coronary heart disease and dia-
betes mellitus[18, 23], whereas all the parallel trials included patients with these risk factors[24,
25, 38]. Therefore, the degree of heterogeneity between studies both in terms of the design and
medications used was relatively high. Moreover, for analysis, data had to be represented as
mean ± SD, hence several mathematical manipulations were needed to transform data into
this format.
Despite these limitations, the current meta-analysis suggests that anti-hypertensive treat-
ments do not worsen leg ischemia and may possibly improve MWD. This is important to con-
firm since lowering BP in patients with PAD has significant potential to reduce cardiovascular
events. Current guidelines recommend the reduction of BP to 140/90 in PAD patients[16,
17] but a recent trial conducted by the SPRINT research group showed that a target of
SBP 120 mmHg among patients at high risk of cardiovascular events, including PAD
patients, resulted in substantially lower rates of cardiovascular events and associated mortality
[43]. It is therefore likely that updated guidelines may advise lowering SBP in high risk patients
to 120 mmHg.
The findings of one of our sub-analyses, that ACE inhibitors did not influence leg outcomes
is in apparent contradiction to a previous meta-analysis which reported that ACE inhibitors
improved walking ability in patients with IC[44]. It should be noted that the prior meta-analy-
sis included two trials which have been subsequently retracted[45, 46] and positive data from
these studies may have contributed to this difference in findings. However the results of this
meta-analysis is comparable to an older meta-analysis which concluded that ACE inhibitors
did not have any significant effect on walking distance and ABPI[47].
In conclusion, this meta-analysis suggests that reducing BP does not worsen leg ischemia in
patients with IC. The role played by anti-hypertensives in improving outcomes is controversial
and lacks sufficient evidence and has been clouded by retraction of two trials that reported
positive outcomes[45, 46]. Large multicenter trials with prolonged anti-hypertensive treatment
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periods are required to clarify the effect of anti-hypertensives on symptoms of IC. However,
designing such trials is difficult due to the convincing data suggesting that patients at high risk
of cardiovascular events, such as PAD patients, should be on anti-hypertensive medications to
reduce the incidence of such events[48, 49].
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